Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00960999 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Phase 2 study of Lung Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 20
- Study locations
NCT00960999 is a Phase 2 study of Lung Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 94 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT00960999, a Phase 2 study of Lung Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which regimen of stereotactic body radiation therapy is more effective in treating patients with non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy regimens and to see how well they work in treating patients with stage I non-small cell lung cancer.
Conditions Studied
Interventions
- RADIATION Single-fraction stereotactic body radiation therapy (SBRT)
- RADIATION Multiple-fraction stereotactic body radiation therapy (SBRT)
Study Locations (20)
California
- Auburn Radiation Oncology - Auburn
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Radiation Oncology Centers - Cameron Park - Cameron Park
- Mercy Cancer Center at Mercy San Juan Medical Center - Carmichael
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
- Community Cancer Center - Normal
- Advocate Lutheran General Cancer Care Center - Park Ridge
- OSF St. Francis Medical Center - Peoria
Florida
- Baptist Cancer Institute - Jacksonville - Jacksonville
- M.D. Anderson Cancer Center at Orlando - Orlando
Indiana
- Parkview Regional Cancer Center at Parkview Health - Fort Wayne
- Memorial Hospital of South Bend - South Bend
Kentucky
- Lucille P. Markey Cancer Center at University of Kentucky - Lexington
- James Graham Brown Cancer Center at University of Louisville - Louisville
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
- Great Lakes Cancer Institute at McLaren Regional Medical Center - Flint
Missouri
- CCOP - Kansas City - Kansas City
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis - St Louis
Colorado
- University of Colorado Cancer Center at UC Health Sciences Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2009-11 |
| Est. Completion | 2018-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00960999
The ClinicalTrials.gov registry entry for NCT00960999 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Single-fraction stereotactic body radiation therapy (SBRT) is the first listed.
NCT00960999 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT00960999 about?
NCT00960999 is a clinical study titled "Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which regimen of stereotactic body radiation ther...
What is the current status of trial NCT00960999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2009-11. Estimated completion is 2018-05-14.
What conditions does trial NCT00960999 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00960999?
The interventions under investigation include: Single-fraction stereotactic body radiation therapy (SBRT) (RADIATION), Multiple-fraction stereotactic body radiation therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT00960999?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00960999 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.